Rafael Medical Technologies secured equity investment from Possis Medical to advance its innovative SafeFlo® IVC filter, targeting the growing U.S. vascular treatment market.

Target Information

Rafael Medical Technologies, an innovative medical device company based in Israel, is primarily focused on developing its proprietary SafeFlo® inferior vena cava (IVC) filter. This filter addresses a critical medical issue by preventing blood clots, which can lead to potentially fatal conditions such as pulmonary embolism (PE). The SafeFlo® IVC filter is designed to be minimally invasive and retrievable, currently in the clinical trial phase in both the United States and Europe. The company is anticipating a 510(k) submission to the FDA within the next 12 to 18 months to facilitate its market entry.

The medical landscape in which Rafael operates is vital, given that over 600,000 people in the U.S. are diagnosed with deep vein thrombosis (DVT) annually—a condition that can result in deadly complications. The strategic timing of Rafael's advancements places them well within an estimated U.S. market for IVC filters expected to grow to nearly $200 million by 2010. This positions Rafael Medical to significantly impact patient care and treatment options in vascular medicine.

Industry Overview

The medical device industry in Israel is recognized as a leader in innovation, with a strong emphasis on research and development. The country is home to numerous biotech firms, making significant contributions to global